BRPI0518933A2 - adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium - Google Patents

adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium

Info

Publication number
BRPI0518933A2
BRPI0518933A2 BRPI0518933-0A BRPI0518933A BRPI0518933A2 BR PI0518933 A2 BRPI0518933 A2 BR PI0518933A2 BR PI0518933 A BRPI0518933 A BR PI0518933A BR PI0518933 A2 BRPI0518933 A2 BR PI0518933A2
Authority
BR
Brazil
Prior art keywords
recombinant
antigens
multivalent
polynucleotide vector
vectors
Prior art date
Application number
BRPI0518933-0A
Other languages
English (en)
Inventor
Menzo Jans Emco Havenga
Ronald Vogels
Jerald Sadoff
David Hone
Yasir Abdul Wahid Sheiky
Katarina Radosevic
Original Assignee
Crucell Holland B V E Aeras Gl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland B V E Aeras Gl filed Critical Crucell Holland B V E Aeras Gl
Publication of BRPI0518933A2 publication Critical patent/BRPI0518933A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ADENOVÍRUS RECOMBINANTE DEFEITUOSO DE REPLICAÇçO, VETOR DE POLINUCLEOTÍDEO RECOMBINANTE, VACINA MULTIVALENTE DA TUBERCULOSE, E, USO DO ANTIGENO TBlO.4 DE MYCOBACTERIUM. A invenção diz respeito a vacinas que compreendem vetores recombinantes, tais como os adenovírus recombinantes. Os vetores compreendem ácidos nucleicos heterólogos codificando para pelo menos dois antígenos de um ou mais bacilos causadores da tuberculose. A invenção também diz respeito ao uso de sítios específicos de reconhecimento da protease ligando antigenos através dos quais os antigenos codificados são separados após a clivagem. Após a clivagem, os antígenos contribuem para aresposta imune de uma maneira separada. Os vetores recombinantes podem compreender um ácido nucleico codificando a protease clivando os ligadores e separando os antígenos. A invenção, além disso, diz respeito ao uso de adjuvantes genéticos codificados pelos vetores recombinantes, em que tais adjuvantes genéticos podem também ser clivados através da presença dos ligadores cliváveis e da protease específica.
BRPI0518933-0A 2004-11-16 2005-11-15 adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium BRPI0518933A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62825304P 2004-11-16 2004-11-16
EP04106074 2004-11-25
US65111305P 2005-02-08 2005-02-08
PCT/EP2005/055984 WO2006053871A2 (en) 2004-11-16 2005-11-15 Multivalent vaccines comprising recombinant viral vectors

Publications (1)

Publication Number Publication Date
BRPI0518933A2 true BRPI0518933A2 (pt) 2008-12-16

Family

ID=34929936

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518933-0A BRPI0518933A2 (pt) 2004-11-16 2005-11-15 adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium

Country Status (14)

Country Link
US (3) US8012467B2 (pt)
EP (1) EP1812580B1 (pt)
JP (1) JP4838259B2 (pt)
KR (1) KR101255870B1 (pt)
CN (2) CN101090974B (pt)
AU (2) AU2005305869B2 (pt)
BR (1) BRPI0518933A2 (pt)
CA (1) CA2586620C (pt)
EA (1) EA012037B1 (pt)
MX (1) MX2007005256A (pt)
NZ (2) NZ581306A (pt)
SG (2) SG159555A1 (pt)
WO (1) WO2006053871A2 (pt)
ZA (1) ZA200703838B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
BRPI0518933A2 (pt) 2004-11-16 2008-12-16 Crucell Holland B V E Aeras Gl adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
WO2007110409A1 (en) * 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
EP2118128B1 (en) * 2007-01-15 2012-11-07 GlaxoSmithKline Biologicals SA Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
GB0719509D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Molecular adjuvant
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
WO2010009346A2 (en) * 2008-07-16 2010-01-21 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
PL2358757T3 (pl) 2008-11-18 2019-02-28 Beth Israel Deaconess Medical Center Szczepionki antywirusowe o ulepszonej immunogenności komórkowej
EP2421557B1 (en) * 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
CN102154324B (zh) * 2010-12-29 2012-11-28 兰州大学 结核分枝杆菌融合蛋白Mtb10.4-Hsp16.3的构建、表达和纯化方法及其应用
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
IN2014CN04742A (pt) 2011-11-28 2015-09-18 Crucell Holland Bv
KR102044051B1 (ko) 2012-03-12 2019-11-12 얀센 백신스 앤드 프리벤션 비.브이. 터미널 말단이 변경된 재조합 아데노바이러스의 배치
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
WO2013158061A1 (en) * 2012-04-16 2013-10-24 Aeras Global Tb Vaccine Foundation Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof
SG11201500171YA (en) 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
US9809801B2 (en) 2013-03-15 2017-11-07 Université De Genève Anti-mycobacterial vaccines
CN103304670B (zh) * 2013-06-03 2015-09-16 中国人民解放军第三〇九医院 结核分枝杆菌特异性融合蛋白疫苗ab及其制备和应用
CN111514314A (zh) 2013-09-19 2020-08-11 扬森疫苗与预防公司 改进的腺病毒配制品
CN103865934B (zh) * 2014-03-26 2017-02-22 中国人民解放军成都军区疾病预防控制中心 银环毒素抗原表位基因及其在基因疫苗及抗原制备中的应用
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CA2952741A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
WO2016198621A1 (en) * 2015-06-12 2016-12-15 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
EA036412B1 (ru) 2015-10-06 2020-11-09 Янссен Вэксинс Энд Превеншн Б.В. Способ обеспечения защиты аденовируса от разрушения, вызванного взаимодействием с пластиком, и применение 2-гидроксипропил--циклодекстрина для защиты аденовируса
BR112018072865A2 (pt) 2016-05-12 2019-04-30 Janssen Vaccines & Prevention B.V. promotor bidirecional potente e equilibrado
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3526236B1 (en) 2016-10-17 2025-12-10 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
CN106754758A (zh) * 2016-12-29 2017-05-31 汕头大学医学院 一种含细胞因子佐剂的重组肠道病毒表型混合系统的构建方法及其应用
JP6721797B2 (ja) 2017-02-09 2020-07-15 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 異種遺伝子発現のための強力で短いプロモーター
CN107602672B (zh) * 2017-08-30 2021-06-18 广州医科大学附属第一医院 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
CN107365365B (zh) * 2017-08-30 2021-01-01 广州医科大学附属第一医院 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
WO2019081750A1 (en) * 2017-10-27 2019-05-02 Statens Serum Institut VACCINE AGAINST POLYGENIC INFLUENZA
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations
WO2024155646A1 (en) * 2023-01-17 2024-07-25 Regents Of The University Of Minnesota Multivalent vaccines against tuberculosis

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042016C (en) 1989-09-19 2004-04-06 Jean Content Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis
EP0499003A1 (en) 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
DK79893D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
JPH09505588A (ja) 1993-11-23 1997-06-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多くの細胞外生成物及びそれらの製造法並びに使用
US6599510B1 (en) * 1993-11-23 2003-07-29 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
NZ309945A (en) 1995-05-23 2001-04-27 Univ California Abundant extracellular products and their use as vaccines
MX9801687A (es) 1995-09-01 1998-11-29 Corixa Corp Compuestos y metodos para el diagnostico de tuberculosis.
US6338852B1 (en) * 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) * 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
EP1203817B9 (en) 1995-09-01 2006-08-16 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6087163A (en) * 1997-02-06 2000-07-11 The Public Health Research Institute Of The City Of New York, Inc. Mycobacterium tuberculosis specific proteins and genes, mixtures of anitgens and uses thereof
US6083716A (en) * 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
CA2268036A1 (en) 1996-10-11 1998-04-23 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
JP2001512435A (ja) 1997-01-21 2001-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 豊富な細胞外産物ならびにそれらの産生および使用方法
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6627198B2 (en) * 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
JP4172598B2 (ja) 1997-04-02 2008-10-29 スタテンス セールム インスティトゥート 結核菌由来の核酸フラグメント及びポリペプチドフラグメント
US7037510B2 (en) * 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO1999004005A1 (en) 1997-07-16 1999-01-28 Institut Pasteur A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
WO1999024577A1 (en) 1997-11-10 1999-05-20 Statens Serum Institut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
TWI243169B (en) 1998-03-02 2005-11-11 Nissan Chemical Ind Ltd Optically active epoxy compound
BR9909472A (pt) 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
US20020150592A1 (en) * 1998-09-18 2002-10-17 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
AU766093B2 (en) 1998-10-08 2003-10-09 Statens Serum Institut Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
AU2594500A (en) 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
US6465633B1 (en) * 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
US20030027774A1 (en) 1999-03-18 2003-02-06 Ronald C. Hendrickson Tuberculosis antigens and methods of use therefor
ATE519854T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
CA2378763A1 (en) 1999-07-13 2001-01-18 Statens Serum Institut Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosis esat-6 gene family
US20020039583A1 (en) 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2001023421A2 (en) 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
EP1229931A4 (en) 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
EP1517913B9 (en) 1999-10-07 2007-08-29 Corixa Corporation A mycobacterium tuberculosis coding sequence for exression of heterologous proteins
WO2001062893A2 (en) 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
GB0006693D0 (en) 2000-03-20 2000-05-10 Glaxo Group Ltd Vaccine
AU2001250294A1 (en) 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US7754201B2 (en) * 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
PT2133100E (pt) 2000-06-20 2012-01-11 Corixa Corp Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
US20020146828A1 (en) * 2001-01-05 2002-10-10 John Hural Microparticles and methods for delivery of recombinant viral vaccines
US7344872B2 (en) 2001-06-22 2008-03-18 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
MXPA04004876A (es) 2001-11-21 2004-07-30 Univ Pennsylvania Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso.
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CA2478508C (en) 2002-04-25 2013-07-02 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
WO2004006952A2 (en) 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20040185555A1 (en) 2003-03-17 2004-09-23 Emini Emilio A. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
KR100992646B1 (ko) * 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
EP1663114A2 (en) * 2003-09-18 2006-06-07 Merck & Co., Inc. Therapeutic immunization of hiv-infected individuals
WO2005061534A2 (en) 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
BRPI0518933A2 (pt) * 2004-11-16 2008-12-16 Crucell Holland B V E Aeras Gl adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
DK1827504T3 (da) * 2004-12-01 2011-08-29 Aeras Global Tb Vaccine Foundation Rekombinante BCG-stammer med forøget evne til at undslippe fra endosomet
CN101595228A (zh) 2005-07-21 2009-12-02 艾博特公司 包括sorf构建体的多基因表达和使用多蛋白、前体蛋白和蛋白酶解的方法

Also Published As

Publication number Publication date
AU2011200749B9 (en) 2012-04-05
ZA200703838B (en) 2012-07-25
CN102220357A (zh) 2011-10-19
EP1812580B1 (en) 2014-12-17
EP1812580A2 (en) 2007-08-01
CN102220357B (zh) 2013-12-25
JP4838259B2 (ja) 2011-12-14
KR101255870B1 (ko) 2013-04-17
EA200701084A1 (ru) 2007-10-26
JP2008520198A (ja) 2008-06-19
CN101090974B (zh) 2011-05-11
CA2586620A1 (en) 2006-05-26
WO2006053871A3 (en) 2006-12-21
US8012467B2 (en) 2011-09-06
MX2007005256A (es) 2008-03-11
EA012037B1 (ru) 2009-06-30
AU2005305869B2 (en) 2010-12-09
CA2586620C (en) 2014-06-03
NZ581306A (en) 2011-03-31
US20090123438A1 (en) 2009-05-14
KR20070091620A (ko) 2007-09-11
US8609402B2 (en) 2013-12-17
SG159555A1 (en) 2010-03-30
AU2011200749B2 (en) 2012-03-01
AU2005305869A1 (en) 2006-05-26
NZ555907A (en) 2009-12-24
AU2011200749A1 (en) 2011-03-10
SG159554A1 (en) 2010-03-30
US20110256166A1 (en) 2011-10-20
WO2006053871A2 (en) 2006-05-26
CN101090974A (zh) 2007-12-19
US8202723B2 (en) 2012-06-19
US20110281347A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
SG159555A1 (en) Multivalent vaccines comprising recombinant viral vectors
Hurtgen et al. Construction and evaluation of a novel recombinant T cell epitope-based vaccine against coccidioidomycosis
DK1802336T3 (da) Malaria primer/boostervacciner
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
DK0996717T3 (da) Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination
WO2006039045A3 (en) Adenoviral vectors able to transduce apcs, potential use in immune response generation
EP1363660A4 (en) HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN
UA103885C2 (en) Immunogenic streptococcus proteins
BRPI0508551A (pt) seqüências de ácidos nucléicos de lactobacillus acidophilus que codificam proteìnas relacionadas à utilização de carboidrato e usos dessas
WO2003066820A3 (en) Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof
Rosenberg et al. Long-term immunity to Trypanosoma cruzi in the absence of immunodominant trans-sialidase-specific CD8+ T cells
BR112013004582A2 (pt) método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
Rao et al. Modulation of host immune responses by overexpression of immunodominant antigens of Mycobacterium tuberculosis in bacille Calmette–Guerin
DE69836520D1 (de) Clostridium perfringens Impfstoff
Sam et al. Synthetic particulate subunit vaccines for the prevention of Q fever
Marchioro et al. Production and characterization of recombinant transmembrane proteins from Mycoplasma hyopneumoniae
Gao et al. Reconstruction of a swine SLA-I protein complex and determination of binding nonameric peptides derived from the foot-and-mouth disease virus
DK1274853T3 (da) Materialer og fremgangsmåder, der angår immunreaktioner på fusionsproteiner
WO2001074845A3 (en) Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
Xue et al. Construction, expression, and characterization of thymosin alpha 1 tandem repeats in Escherichia coli
Suphatpahirapol et al. Expression of a leptospiral leucine-rich repeat protein using a food-grade vector in Lactobacillus plantarum, as a strategy for vaccine delivery
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
Freer et al. Identification and molecular cloning of a novel secretion antigen from Mycobacterium tuberculosis and Mycobacterium bovis BCG
Shahzad et al. Evaluation of DNA vaccines encoding M. Tb gene Bfrb and Mpt32 in mice model
Cao et al. Secretory expression and purification of recombinant Escherichia coli heat-labile enterotoxin B subunit and its applications on intranasal vaccination of hantavirus

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.